COPD is a disease that damages your lungs over time. It may start with mild symptoms and then get worse. Treatment can help symptoms and slow disease progression. Chronic obstructive pulmonary ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Erdosteine is a multimechanism, mucolytic agent that decreases the sputum viscoelastic properties and bacterial adhesion to the cell membrane, endowed with bronchial anti-inflammatory activity and ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Virtual pulmonary rehabilitation is a safe, effective alternative to traditional pulmonary rehabilitation programs for people ...

As COPD care moves toward precision-guided approaches, this study reinforces the value of immunologic markers in guiding treatment strategies beyond symptom control alone.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Mepolizumab has been developed for the treatment of a range of IL-5 mediated ... and exacerbations in up to 40% of people with COPD. Patients with COPD experience persistent respiratory symptoms such ...

The right treatment plan can help you control your COPD symptoms and avoid exacerbations (flareups). These include shortness of breath, wheezing, cough, chest tightness, and excess mucus production.